Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of…

Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study  The Lancet

Follow this link:

Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of...

Read more
Sales of the Mesenchymal Stem Cells Market to Anticipated to Exceed US$ XX by2020 Bulletin Line – Bulletin Line

Global Mesenchymal Stem Cells market study presents an in-depth scenario Which is segmented according to manufacturers, product type, applications, and areas. This segmentation will provide deep-dive analysis of the Mesenchymal Stem Cells industry for identifying the growth opportunities, development trends and factors limiting the growth of the market. This report offers forecast market information based on previous and current Mesenchymal Stem Cells industry scenarios and growth facets. All the key regions covered in Mesenchymal Stem Cells report are North America, Europe, Asia-Pacific, South America, Middle East and Africa. The Mesenchymal Stem Cells market share and market outlook of each area from 2020-2027 are presented in this report. A deep study of Mesenchymal Stem Cells market dynamics can help the market aspirants in identifying the business opportunities which will lead to accumulation of revenue. This section can effectively determine the Mesenchymal Stem Cells risk and key market driving forces.

Request Sample Report @

The Mesenchymal Stem Cells report is segmented to provide a clear and Precise view of the international Mesenchymal Stem Cells market statistics and market estimates. Mesenchymal Stem Cells report Information represented in the form of graphs, charts, and figures will show the Mesenchymal Stem Cells growth speed, volume, goal consumer analysis. This report introduces the significant data to all Mesenchymal Stem Cells industry aspirants which will facilitate useful business decisions.

Some of the major companies operating in the global mesenchymal stem cell market are EMD Millipore Corporation, Cell Applications, Inc., Cyagen Biosciences, Inc., Genlantis, Inc., Advanced Cell Technology Incorporated, Stemcell Technologies Inc., Celprogen, Inc., Stemedica Cell Technologies, Aastrom Biosciences and ScienCell Research Laboratories.

Key points covered in the report

Request Report Methodology @

The Mesenchymal Stem Cells report cover following data points:

Part 1: This section enlists the global Mesenchymal Stem Cells marketplace Summary, covering the simple market introduction, market evaluation by kind, software, and regions. The major Mesenchymal Stem Cells producing areas include North America, Europe, Asia-Pacific, Middle-East, and Africa. Mesenchymal Stem Cells industry states and outlook (2020-2027) is introduced in this part. Additionally, Mesenchymal Stem Cells market dynamics stating the opportunities, market risk, and key driving forces are researched.

Part 2: This part covers Mesenchymal Stem Cells manufacturers profile based On their small business overview, product type, and program. Additionally, the sales volume, Mesenchymal Stem Cells product cost, gross margin analysis, and Mesenchymal Stem Cells market share of each participant is profiled in this report.

Part 3 and Part 4: This component presents the Mesenchymal Stem Cells competition Based on sales, earnings, and market share of every manufacturer. Part 4 covers the Mesenchymal Stem Cells market situation based on areas. Region-wise Mesenchymal Stem Cells sales and expansion (2015-2019) is analyzed in this report.

Part 5 and Part 6: These two sections cover the North America and Europes Mesenchymal Stem Cells industry by countries. Under this Mesenchymal Stem Cells earnings, market share of those countries like USA, Canada, and Mexico is supplied. Beneath Europe Mesenchymal Stem Cells report includes, the states such as Germany, UK, France, Russia, Italy, Russia and their sales and growth is covered.

For any queries get in touch with Industry Expert @

Sales revenue and expansion for the regions like Asia-Pacific, South America, Middle East & Africa. The earnings and expansion in these areas are introduced within this Mesenchymal Stem Cells business report.

Part 10 and Part 11: This part depicts the Mesenchymal Stem Cells market Share, earnings, sales by product type and application. The Mesenchymal Stem Cells sales growth seen during 2012-2020 is covered in this report.

Associated with Mesenchymal Stem Cells economy (2020-2027) for each area. The sales channels such as direct and indirect Mesenchymal Stem Cells marketing, traders, distributors, and future trends are presented within this report.

Part 14 and Part 15: These components present Mesenchymal Stem Cells market crucial Research findings and conclusion, study methodology, and information sources are covered.

Therefore, Global Mesenchymal Stem Cells report is a whole blend covering all The very important market aspects.

Read more here:

Sales of the Mesenchymal Stem Cells Market to Anticipated to Exceed US$ XX by2020 Bulletin Line - Bulletin Line

Read more
Global Jaw Crushers Market 2020 Analyzed With Trends And Opportunities By 2025 – 3rd Watch News

The report titled Jaw Crushers Market Research 2020 begins from overview of industry chain structure, and describes industry environment, and analyses market size of Jaw Crushers. Initially, the report focuses on the current state of the Jaw Crushers market and then the detailed analysis has been provided based on a systematic and detailed segmentation and sub-segmentation. It identifies the dynamics affecting each segment within it. Jaw Crushers market report profiles some of the key technological developments in the recent times.

Get Free Sample Of This Research

In order to forecast and strengthen the productivity of the Jaw Crushers industry, a detailed study is necessary, which has been explained in the report. The Jaw Crushers industry report summarizes the market insights that are key drivers for growth of the Jaw Crushers sales market over the forecast period (2020-2025). The report is confident in meeting clients need and expectations as we have used innovative business models that focus on delivering high-quality contents. The report studies the Jaw Crushers market in terms of product type, size, and region. Growth behavior in the past of key segments under each criterion is examined, using which their market size and revenue contribution has estimated. The leading players in the Jaw Crushers market have been profiled in this report.

Request sample copy of Jaw Crushers market research at:

The report covers crucial entities of the Jaw Crushers market such as market share, wide variety of applications, market trends, demand and supply, market growth outlook, industry value and volume, manufacturing capacity and price ratio of the Jaw Crushers market during the estimated period from 2015 to 2025.

The Jaw Crushers Market Report deals with following key objectives:

Access Details Table Of Content

The following points give the overview of the market analysis, focusing on thorough study of the Jaw Crushers Market Research Report:

For market chain analysis, the Jaw Crushers report shades light on marketing channels, upstream raw materials, downstream client survey, market development trend and proposals which specifically comprises valuable information on major raw materials suppliers, distributors, major manufacturing equipment suppliers, and key consumers with their contact information. Furthermore, the report deploys the SWOT analysis tool so that you can try to be one step ahead of your competitors. The report will be beneficial for entrepreneurs, individuals, merchants, large organizations, and start-ups to secure funding.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Read more here:

Global Jaw Crushers Market 2020 Analyzed With Trends And Opportunities By 2025 - 3rd Watch News

Read more
Allogeneic Mesenchymal stem cells Market is on Course to Grow at a CAGR of XX% Over the Forecast Period 2018 2028 – 3rd Watch News

A new intelligence report Allogeneic Mesenchymal stem cells Market has been recently added to Adroit Market Research collection of top-line market research reports. Global Allogeneic Mesenchymal stem cells Market report is a meticulous all-inclusive analysis of the market that offers access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual information sourced from authentic industry experts and extensive primary industry research, the report offers insights on the historic growth pattern of Allogeneic Mesenchymal stem cells Market and current market scenario. It then provides short- and long-term market growth projections.

Projections are purely based on the detailed analysis of key market dynamics that are expected to influence Allogeneic Mesenchymal stem cells Market performance and their intensity of impacting market growth over the course of assessment period.

Request Sample Report @

In addition to evaluation of dynamics, the report provides in-depth examination of key industry trends that are expected to act more prominently in global Allogeneic Mesenchymal stem cells Market. The study also offers valued information about the existing and upcoming growth opportunities in Allogeneic Mesenchymal stem cells Market that the key players and new market entrants can capitalize on.

Competitive companies and manufacturers in global market

key players operating in the Allogeneic Mesenchymal stem cells market are Aastrom Biosciences, Inc. Mesoblast Ltd., Celgene Corporation, and StemCells, Inc.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @

Opportunity assessment offered in this Allogeneic Mesenchymal stem cells Market report is important in terms of understanding the lucrative areas of investment, which prove to be the actionable insights for leading market players, suppliers, distributors, and other stakeholders in Allogeneic Mesenchymal stem cells Market.

In-depth global Allogeneic Mesenchymal stem cells Market taxonomy presented in this report provides detailed insights about each of the market segments and their sub-segments, which are categorized based on t par various parameters. An exhaustive regional analysis of global Allogeneic Mesenchymal stem cells Market breaks down global market landscape into key geographies.

Regional outlook and country-wise analysis of Allogeneic Mesenchymal stem cells Market allows for the evaluation of multi-faceted performance of market in all the key economies. This information intends to offer a broader scope of report to readers and identify the most relevant profitable areas in global market place.

Key Regions and Countries Covered in Global Allogeneic Mesenchymal stem cells Market Report-

Taxonomy and geographical analysis of the global Allogeneic Mesenchymal stem cells Market enables readers to spot profits in existing opportunities and capture upcoming growth opportunities even before they approach the market place. The analysis offered in report is purely intended to unroll the economic, social, regulatory and political scenarios of the market specific to each region and country, which could help potential market entrants in Allogeneic Mesenchymal stem cells Market landscape to understand the nitty-gritty of target market areas and devise their strategies accordingly.

For any queries get in touch with Industry Expert @

Allogeneic Mesenchymal stem cells Market Table of Contents

Read the original here:

Allogeneic Mesenchymal stem cells Market is on Course to Grow at a CAGR of XX% Over the Forecast Period 2018 2028 - 3rd Watch News

Read more
Mesenchymal Stem Cells Market is Awaited to Grow at a high CAGR over the forecast period 2020 and 2026 – 3rd Watch News

The global Mesenchymal Stem Cells Market analysis provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Mesenchymal Stem Cells Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Request PDF Research Report Brochure @

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Major Players Are:Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

Regions & Countries Mentioned In The Mesenchymal Stem Cells Market Report:

Key Highlights of the Table of Contents:

Request a sample copy of this [emailprotected]

Note:*The sample copy includes Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Role of Mesenchymal Stem Cells Market Report:

The global Mesenchymal Stem Cells Market has been appearing as one of the most profit-making businesses in the globe. The market has been exhibiting considerable growth figures led by raw material affluence, increasing population, expanding regions, rapid elevating demand, and advanced technologies. The report is likely to be performed vigorously in the upcoming phase, analysts predicted after studying the market at a minute level.

Various analytical tools such as SWOT, Feasibility analysis, Porters Five Forces analysis, Value Chain analysis, and Capacity utilization analysis are implemented while evaluating the Mesenchymal Stem Cells Market which certainly helps a reader to get a deeper perception of the market and its participants. Additionally, it covers a cardinal evaluation of market history, patterns, changing dynamics, market and manufacturing trends, demand and supply activities, and technological development.

Buy-Now this Research Report @

Note: *Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights,1001 4th Ave, #3200,Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]Visit Blog:

Read the original:

Mesenchymal Stem Cells Market is Awaited to Grow at a high CAGR over the forecast period 2020 and 2026 - 3rd Watch News

Read more
Biopreservation Market 2020 Global Analysis, Size, Growth, Covid-19 Impact Analysis, Leading Players, Merger, Acquisition, Opportunity, With Regional…

Biopreservation Market Overview

Biopreservation is the preservation of biological materials through the use of natural flora and its antibacterial products and forms an integral part in both the food and healthcare industry. The global biopreservation market is on an upward growth trajectory and is estimated to strike a CAGR of 11.2% over the forecast period of 2018-2023, predicts Market Research Future (MRFR).

Adult mesenchymal stem cells have gained huge momentum as it is a promising source for cell therapies and tissue engineering applications due to which the demand for stem cell preservation has increased drastically. Biopreservation is a crucial aspect of cell and gene-based therapy biopreservation. Growth in number of cryogenic storage facilities is expected to induce high demand within the global biopreservation market.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @

Biopreservation has substantial significance in the food industry. Biopreservation is extensively used in the preservation of various food products such as dairy and meat products since they can cause great economic loses. Surging awareness regarding the risks associated with the transmission of foodborne pathogens has evoked greater interest in the application of biopreservation techniques in food safety and food preservation. Moreover, biopreservation is the only viable technique which can be applied to certain food products where other techniques can be used. Furthermore, microbiological safety standards and rise in the incidence of food spoilage, and growing consumption of precooked foods are other factors which generate massive demand for biopreservation from the food industry.

The global biopreservation market is also growing in tandem with recent advances in interrelated, emerging and evolving field of biospecimen procurement, processing, preservation and banking, distribution, and use.

On the downside, biopreservation instruments and their maintenance is a cost-intensive which is a major impediment to the market growth. Moreover, stability issues surrounding specimen and dearth of trained professionals to perform and handle the biopreservation process are other possible bottlenecks to the growth of the global biopreservation market.

Biopreservation MarketSegmentation

The global biopreservation market has been segmented based on product, biospecimen, and application.

By product, the global biopreservation market has been segmented into media and equipment. The media segment has been further segmented into nutrient media, sera, and growth factors and supplements.

The equipment segment has been further segmented into temperature control systems, accessories, alarms & monitoring systems, incubators, centrifuges, and other equipment. The temperature control systems sub-segment has been further segmented into freezers, cryogenic storage systems, thawing equipment, and refrigerators.

By biospecimen, the global biopreservation market has been segmented into human tissue samples, organs, stem cells, and other biospecimens.

By application, the global biopreservation market has been segmented into regenerative medicine, biobanking, and drug discovery. The regenerative medicine segment has been further segmented into cell therapy, gene therapy, and others.

The biobanking segment has been further segmented into human eggs, veterinary IVF, and human sperm.

Biopreservation MarketRegional Analysis

By region, the global biopreservation market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

The Americas account for the largest share of the globalbiopreservation market. Extensive utilization of advanced technologies, high expenditure on R&D activities, and the existence of key players in the region are favoring the growth of the global biopreservation market in the Americas region. Moreover, merger and acquisition have been adopted as key strategies by market players which further contributes to the growth of the market.

Europe is the second largest market within the global biopreservation market. Prevalent trend of stem cell preservation coupled with high birth rate in the region substantiates the growth of the market. The rise in a number of sperm and egg banks in the region is also contributing positively to the market growth.

APAC biopreservation market is estimated to expand at a relatively faster rate than other markets. Booming population, the surge in the awareness level of stem cell preservation and persistent development within the healthcare sector are factors triggering growth within the APAC market.

MEA market accounts for the least share of the global market owing to the underdeveloped healthcare sector in the region, lack of technical know-how and poor medical facilities.

Biopreservation MarketCompetitive Landscape

Thermo Fisher Scientific, Inc., Core Dynamics, Ltd., ATLANTA BIOLOGICALS, VWR International, LLC., BioLifeSolutions Inc., Princeton CryoTech, Lifeline Scientific, QIAGEN, Cesca Therapeutics Inc., Panasonic Biomedical, Inc., Chart Industries, Sigma-Aldrich Co., CUSTOM BIOGENIC SYSTEMS., BioCision., and Biomatrica, Inc. are the key players in the global biopreservation market.

Biopreservation Industry Updates

March 2019- BioLife Solutions, Inc., a leading manufacturer, marketer, and developer of proprietary cell and tissue hypothermic storage and cryopreservation freeze media, announced the acquisition of Astero Bio, a company focused on innovation, design, development, and commercialization of novel automated thawing devices. The transaction was closed for an amount of USD 8 Mn.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @

About Market Research Future:

AtMarket Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.


Akash Anand

Market Research Future

+1 646 845 9312


NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Originally posted here:

Biopreservation Market 2020 Global Analysis, Size, Growth, Covid-19 Impact Analysis, Leading Players, Merger, Acquisition, Opportunity, With Regional...

Read more
Global Mesenchymal Stem Cells Market 2020 Coronavirus (COVID-19) Updated Analysis By Product (MSC-AT, MSC-UC, MSC-BM, Others); By Application…

Mesenchymal Stem Cells Industry Overview Competitive Analysis, Regional and Global Analysis, Segment Analysis, Market Forecasts 2026

The globalMesenchymal Stem Cells marketshave undergone huge change in the last few months. These changes were due to the outbreak of the pandemic which was first detected in the Wuhan city of China. COVID-19 which has occurred due to the coronavirus has taken many lives of people around the world. As the disease is spreading at a rapid rate many of the countries have ordered lockdown for maintaining social distancing. Due to the lockdown, many of the industries have halted their manufacturing units. There have been restrictions for cross border trading within the countries and also within the states. Owing to these conditions, trading conditions in various regions have been affected badly. The overall countries in the world are facing economic crisis thus affecting some of the major markets in the world.

Request Free Sample Copy of Mesenchymal Stem Cells Market Research Report@

The research analysts from theMarket Research Storehave conducted a detailed study about the global Mesenchymal Stem Cells market. Owing to the above mentioned conditions, the global Mesenchymal Stem Cells market has undergone several changes on the global platform. All these updates are mentioned in the Mesenchymal Stem Cells market report study. The research analysts have conducted a thorough primary and secondary research for updating the market statistics as per the current market scenario. The detailed Mesenchymal Stem Cells market report is of over 150 pages including more than 30 tables and around 20 figures. The report includes pictorial representations of the market data in order to understand the Mesenchymal Stem Cells market in a simple and easy way.

The data that is included about the Mesenchymal Stem Cells market incorporates historical data from 2016 to 2019 and forecasts data from 2020 to 2026. The major players that are functioning in the Mesenchymal Stem Cells market areIrvine Scientific, Biological Industries, PromoCell GmbH, Miltenyi Biotec, Lonza, STEMCELL Technologies, Bio-Techne, Mesoblast, Axol Bioscience, Thermo Fisher. Details about all the market players, distributors, suppliers, and retailers are profiled in the Mesenchymal Stem Cells market report.

Read Detailed Index of full Research Study at::

The Mesenchymal Stem Cells market is segmented into{MSC-AT, MSC-UC, MSC-BM, Others}; {Cell-based Screening Assays, Gene Therapy and Transplantation, Cell Differentiation and Gene Regulation}. Each of the market segments is described in detail within the report. Data about the segments are represented in both qualitative and quantitative format, thus enabling to understand the market in detail.

Major Advantages for Mesenchymal Stem Cells Market:

Well-organized description of the international Mesenchymal Stem Cells market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas. The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the Mesenchymal Stem Cells industry. The Mesenchymal Stem Cells market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis. The current market is quantitatively reviewed from 2019 to 2028 to pinpoint the monetary competency of the global Mesenchymal Stem Cells market. Last but not least, PORTERS Five Forces Analysis shows the effectiveness of the customers and providers from a global perspective.

If Any Inquiry of Mesenchymal Stem Cells Report:

Read more:

Global Mesenchymal Stem Cells Market 2020 Coronavirus (COVID-19) Updated Analysis By Product (MSC-AT, MSC-UC, MSC-BM, Others); By Application...

Read more
Mesenchymal Stem Cells Market Growth By Manufacturers, Type And Application, Forecast To 2026 – 3rd Watch News

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Mesenchymal Stem Cells Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Mesenchymal Stem Cells market.

The research study includes the latest updates about the COVID-19 impact on the Mesenchymal Stem Cells sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Mesenchymal Stem Cells manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @

The Mesenchymal Stem Cells market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Mesenchymal Stem Cells market.

This study analyzes the growth of Mesenchymal Stem Cells based on the present, past and futuristic data and will render complete information about the Mesenchymal Stem Cells industry to the market-leading industry players that will guide the direction of the Mesenchymal Stem Cells market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Mesenchymal Stem Cells market. Additionally, it includes a share of each segment of the Mesenchymal Stem Cells market, giving methodical information about types and applications of the market.

Reasons for Buying Mesenchymal Stem Cells Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Mesenchymal Stem Cells market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @

In the end, the Mesenchymal Stem Cells market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Mesenchymal Stem Cells market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Wireless Display Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Wind Turbine Composites Material Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

3D Food Printing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Offshore Wind Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Machine Vision Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original here:

Mesenchymal Stem Cells Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Read more
Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19…

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that an expanded access protocol (EAP) has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome (MIS-C). Patients aged between two months and 17 years may receive one or two doses of remestemcel-L within five days of referral under the EAP.

The protocol was filed with the United States Food and Drug Administration (FDA) and provides physicians with access to remestemcel-L for an intermediate-size patient population1 under Mesoblast’s existing Investigational New Drug (IND) application. According to the FDA, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

MIS-C is a life-threatening complication of COVID-19 in otherwise healthy children and adolescents that includes massive simultaneous inflammation of multiple critical organs and their vasculature. In approximately 50% of cases this inflammation is associated with significant cardiovascular complications that directly involve heart muscle and may result in decreased cardiac function. In addition, the virus can result in dilation of coronary arteries with unknown future consequences. Recent articles from Europe and the United States have described this disease in detail.2-5

Mesoblast Chief Medical Officer Dr Fred Grossman said: The extensive body of safety and efficacy data generated to date using remestemcel-L in children with graft versus host disease suggest that our cellular therapy could provide a clinically important therapeutic benefit in MIS-C patients, especially if the heart is involved as a target organ for inflammation. Use of remestemcel-L in children with COVID-19 builds on and extends the potential application of this cell therapy in COVID-19 cytokine storm beyond the most severe adults with acute respiratory distress syndrome.”

Remestemcel-L Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor and is administered in a series of intravenous infusions. Remestemcel-L is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in several diseases by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.; NCT04456439 2.Lancet2020; May 7. DOI: 3.Lancet. 2020; (May 13) 4. 5.

About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast’s Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward- looking statements include, but are not limited to, statements about: the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

Read the rest here:

Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19...

Read more
BCLI: KOL Event Gives Overview of the use of NurOwn in Alzheimer’s Disease; Raising Valuation to $25/Share – Zacks Small Cap Research

By David Bautz, PhD



Business Update

KOL Event for Alzheimers Program

On July 8, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted a Key Opinion Leader (KOL) webinar to discuss the companys upcoming Phase 2a clinical trial of NurOwn in patients with Alzheimers Disease (AD). The event included presentations by two of the lead investigators for the upcoming trial, Dr. Philip Scheltens, Professor of Cognitive Neurology and Director of the Alzheimer Centre at VU University Medical Center in Amsterdam, Netherlands, and Dr. Bruno Dubois, Professor of Neurology at the Neurological Institute of the Salptrire University Hospital in Paris, France. The presentation can be found here.

The companys Phase 2a trial (BCT-201-EU) is expected to enroll approximately 40 patients with prodromal to mild AD. It will be taking place at medical centers in France and the Netherlands. To be eligible for the trial, patients must have been diagnosed with prodromal to mild dementia at least six months prior to enrollment. In addition, patients must score between 20-30 on the Mini-Mental State Exam (MMSE) and have a Clinical Dementia Rating (CDR) global score of 0.5-1.0. The MMSE is a series of questions that are designed to assess a patients mental skills, with the maximum score being 30 points and a score of 20-24 suggesting mild dementia. The CDR is a scale used to characterize six domains of cognitive and functional performance with a score of 0.5 suggesting very mild dementia and a score of 1.0 suggesting mild dementia.

The primary objective of the trial is to assess the safety and tolerability of three intrathecal injections of NurOwn in AD patients. Following bone marrow aspiration during a 10-week run-in period, patients will be treated three times with NurOwn, with eight weeks between treatments. Follow-up visits will occur 12 and 26 weeks following the final injection of NurOwn for a total trial length of 52 weeks. The following figure gives an overview of the trial design.

Cerebrospinal fluid (CSF) and serum will be collected prior to treatment and again at Weeks 0, 8, and 16 to assess changes in various neurotropic, neurodegenerative, and inflammatory factors (e.g., VEGF, HGF, NfL, NfH, MCP-1, IL-6), markers associated with amyloid deposition (e.g., a40, a42), and markers of tau protein levels (e.g., p-tau, t-tau). Additional clinical outcome measures will be analyzed through administration of the following tests:

Clinical Dementia Rating ScaledSum of Boxes (CDR-SB)

Free and Cued Selective Reminding Test (FCSRT)

Neuropsychological Test Battery (NTB)

Delis-Kaplan Executive Function System (D-KEFS) subtests

Mini Mental State Examination(MMSE)


Alzheimers Disease

Alzheimers disease (AD) is the most common form of dementia in older adults. The disease is named after Dr. Alois Alzheimer, who identified the first case in a 50-year-old woman named Auguste Deter in 1902. Dr. Alzheimer followed her case until her death in 1906, at which point he first publicly reported on it (Alzheimer, 1907).

After Ms. Deters death, Dr. Alzheimer examined her brain and found many abnormal clumps (now known as amyloid plaques) and tangled bundles of fibers (now known as neurofibrillary tangles). Over the next five years, 11 similar cases were reported in the medical literature, with some of them already using the term Alzheimers disease (Berchtold et al., 1998).

The most common early symptom of AD is a gradually worsening ability to remember new information. This is due to neurons associated with forming new memories dying off first. As neurons in other parts of the brain die, individuals experience different symptoms, which include:

Memory loss that disrupts daily life

Inability to plan or solve problems

Difficulty completing familiar tasks

Confusion with location and time

Difficulty with visual images and spatial relationships

Problems with words in speaking or writing

Withdrawal from social activities

Changes in mood, including apathy and depression

Each person progresses through AD at a different rate, and little is known about how or why there is such a marked variation, thus predicting how it will affect someone is quite difficult. One thing that is common to everyone diagnosed with AD is that his or her cognitive and functional abilities will gradually decline. As the disease progresses symptoms can include confusion, irritability, aggression, mood swings, and long-term memory loss. In the final advanced stage of the disease, people need help with the basic activities of living (e.g., bathing, dressing, eating, and using the restroom), they lose the ability to communicate, fail to recognize loved ones, and eventually become bed bound and reliant on round-the-clock care (Frstl et al., 1999). The inability to move makes them more prone to infections, including pneumonia, which are often a contributing factor to the death of those with AD.

Competing Theories for the Cause of Alzheimers

The root cause of Alzheimers is still unknown; however, it is likely to involve a number of different factors as opposed to being due to one single cause. These factors are likely a combination of genetic, environmental, and lifestyle. There are a number of hypotheses that exist to explain the cause of the disease, with the two dominant hypotheses focused on amyloid and tau.

Amyloid hypothesis: This hypothesis proposes that extracellular beta-amyloid deposits are the fundamental cause of the disease (Hardy et al., 1991). Beta-amyloid is a fragment of the larger protein amyloid precursor protein (APP), mutations of which are known to cause FAD. Several lines of evidence support the amyloid hypothesis: 1) the location of APP is on chromosome 21, while those with Down Syndrome (trisomy 21) almost all show signs of AD by 40 years of age (Lott et al., 2005); 2) APOE4 is a major genetic risk factor for AD, and while apolipoproteins enhance the breakdown of beta-amyloid, some isoforms are less capable of performing this task than others, leading to more beta-amyloid buildup on the brain (Polvikoski et al., 1995); 3) mice that harbor a mutant form of APP develop amyloid plaques and Alzheimers-like pathology (Games et al., 1995). Lastly, amyloid plaques are readily identifiable by microscopy in the brains of AD patients (Tiraboschi et al., 2004). While the brains of many older individuals develop some plaques, the brains of AD patients show severe pathological changes specifically within the temporal neocortex (Bouras et al., 1994).

Tau hypothesis: Tau is a protein located mainly within the axonal compartment of neurons and is an important element in microtubule stabilization and neurite outgrowth. In AD, a proportion of tau protein becomes abnormally phosphorylated, dissociates from axonal microtubules, and accumulates in paired helical filaments inside the neuron (Goedert et al., 1991). When this occurs, the microtubules disintegrate causing the collapse of the neurons transport system (Igbal et al., 2005). Just as with beta-amyloid plaques, tau tangles are readily observable in the brains of those affected by AD.

In addition to amyloid and tau, inflammation has been an underappreciated and often overlooked mediator in patients with AD (Akiyama et al., 2000). A multitude of inflammatory markers are found in AD patients brains and a number of studies have shown a link between chronic inflammation and an increased risk of developing AD (Walker et al., 2017; Tao et al., 2018). Thus, a treatment such as NurOwn that can decrease inflammatory mediators could prove beneficial in AD patients.

On Track to Repot Topline Data from Phase 3 ALS Trial in 4Q20

On July 2, 2020, BrainStorm announced that all doses have been administered in the pivotal Phase 3 trial ofrecen NurOwn in patients with amyotrophic lateral sclerosis (ALS) and that it remains on track to report topline data in the fourth quarter of 2020.

The ongoing randomized, double blind, placebo controlled, multi-dose Phase 3 clinical trial is testing the ability of NurOwn to alter disease progression as measured by the ALSFRS-R (NCT03280056). Cells were extracted once from each patient prior to treatment, with all administrations of NurOwn derived from the same extraction of cells due to a cryopreservation process the company developed for long-term storage of mesenchymal stem cells (MSC). Just as with the companys prior studies, there was a 3-month run-in period prior to the first treatment with two additional NurOwn treatments occurring two and four months following the first treatment. The company is focusing the trial on faster-progressing ALS patients since those patients demonstrated superior outcomes in the Phase 2 trial of NurOwn.

BrainStorm Joins Russell 2000 and Russell 3000; Granted SME Status by EMA

On June 23, 2020, BrainStorm announced that its shares would be included in the Russell 2000 Index and the Russell 3000 Index. The annual reconstitution of the Russell indexes is done to capture the 4,000 largest U.S. stocks by market capitalization.

On June 15, 2020, BrainStorm announced that the company has been granted Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency (EMA). SME status allows the company to participate in a number of financial incentives including a 90-100% reduction in the EMA fee for scientific advice, clinical study protocol design, endpoints and statistical considerations, quality inspections of facilities, and fee waivers for selective EMA pre- and post-authorization regulatory filings, including Orphan Drug and PRIME designations.


Were excited about the potential for NurOwn in AD and we look forward to the initiation of the Phase 2a trial later in 2020. We have recently made a few changes to our model, including the inclusion of NurOwn in AD and lowering of the discount rate from 20% to 15% for all indications. We model for the company to file for approval of NurOwn in AD in 2026 and to be granted approval in 2027. We currently estimate peak sales of over $2 billion for NurOwn in AD in both the U.S. and E.U. Using a 25% probability of approval leads to an NPV of $113 million. Combined with the NPV for NurOwn in ALS ($700 million) and MS ($41 million) along with the companys current cash position and potential cash from warrants leads to a valuation for the company of a bit less than $900 million. Dividing by the companys current fully diluted share count of 35.7 million leads to a valuation of $25 per share.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.

The rest is here:

BCLI: KOL Event Gives Overview of the use of NurOwn in Alzheimer's Disease; Raising Valuation to $25/Share - Zacks Small Cap Research

Read more